Taiwan, January 7, 2022 –For all diagnostic procedures to test COVID-19, performing these tests at POC or near-POC requires a suitable and sufficient risk assessment and implementation of appropriate control measures. It is essential that the rapid testing procedure, which may involve swab stirring/mixing into an elution buffer with the potential for associated generation of aerosols, does not place individuals performing these tests at an increased risk of SARS-CoV-2 exposure. It is therefore highly desirable that rapid testing procedures include a step that reduces the titer of infectious virus presents, e.g., by eluting samples into an effective lysis buffer.
In a study to assess the inactivation effectiveness of sampling buffers used, the UK National Infection Service (NIS) laboratories recently published in the Nature Scientific Reports to demonstrated the VitaPCR™ sample collection buffer is able to inactivate SARS-CoV-2 effectively, which provides clinicians in the front line with sufficient protection against SARS-CoV-2.
According to the study results, a >5.0 log10 reduction in SARS-CoV-2 titer was confirmed after one-minute treatment with VitaPCR™ sample collection buffer, which went up to 6.2 log10 reduction after a five-minute mixing. Data presented in this study showed the capability of VitaPCR™ sample collection buffer to ensure the protection of test operators, which also meets the requirement of the British European standard BS EN 14476 for effectiveness against viruses.
VitaPCR™ sample collection buffer, the next-generation (guanidine-free) nucleic acid extraction buffer, not only inactivates SARS-CoV-2 during contact but also eliminates the chemical hazards associated with conventional guanidine-based reagents in diagnostic procedures.
For more information, please refer to https://rdcu.be/cEsqk or contact us at: service@credodxbiomed.com
